Vatalanib (succinate)

• UNSPSC Description:

  Vatalanib (PTK787) succinate is a potent and orally active VEGFR inhibitor with IC50s of 37 nM, 77 nM, 270 nM, 660 nM, 730 nM, 1400 nM, and 580 nM for KDR, Flt-1, Flk, Flt-4, c-Kit, c-Fms, and PDGFR-β, respectively[1].

• Target Antigen:

  VEGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/vatalanib-succinate.html

• Solubility:

  10 mM in DMSO

• Smiles:

  ClC(C=C1)=CC=C1NC2=C3C(C=CC=C3)=C(CC4=CC=NC=C4)N=N2.OC(CCC(O)=O)=O

• Molecular Weight:

  464.90

• References & Citations:

  [1]J M Wood, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000 Apr 15;60(8):2178-89.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  212142-18-2